Trial Profile

A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deutivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary) ; VX 118 (Primary) ; VX 828 (Primary) ; Itraconazole; Midazolam
Indications Cystic fibrosis
Focus Adverse reactions; Pharmacokinetics
Sponsors Vertex Pharmaceuticals

Most Recent Events

30 May 2025 Planned number of patients changed from 225 to 255.
30 May 2025 Planned End Date changed from 31 Dec 2025 to 5 Feb 2026.
30 May 2025 Planned primary completion date changed from 30 Apr 2025 to 5 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com